The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma
| Title: | The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma |
|---|---|
| Authors: | Marta Maschio PhD, Alessia Zarabla PhD, Andrea Maialetti PhD, Francesco Marchesi PhD, Diana Giannarelli PhD, Svitlana Gumenyuk PhD, Francesco Pisani PhD, Daniela Renzi PhD, Edvina Galiè PhD, Andrea Mengarelli PhD |
| Source: | Integrative Cancer Therapies, Vol 18 (2019) |
| Publisher Information: | SAGE Publishing, 2019. |
| Publication Year: | 2019 |
| Collection: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Background and Aims: In cancer patients, a common complication during chemotherapy is chemotherapy-induced peripheral neuropathy (CIPN). For this reason, we decided to conduct a phase II prospective study on 33 patients with multiple myeloma at first diagnosis, to evaluate whether a nutraceutical compound given for 6 months during bortezomib (BTZ) treatment succeeded in preventing the onset of neurotoxicity. Methods: Neurological evaluation, electroneurography, and functional and quality of life (QoL) scales were performed at baseline and after 6 months. We administered a tablet containing docosahexaenoic acid 400 mg, α-lipoic acid 600 mg, vitamin C 60 mg, and vitamin E 10 mg bid for 6 months. Results: Concerning the 25 patients who completed the study, at 6-month follow-up, 10 patients had no neurotoxicity (NCI-CTCAE [National Cancer Institute-Common Terminology Criteria for Adverse Events] = 0), while 13 progressed to NCI-CTCAE grade 1, 1 had NCI-CTCAE grade 1 with pain, and 1 experienced a NCI-CTCAE grade 2. Painful symptoms were reported only in 2 patients, and we observed stability on functional and QoL scales in all patients. None of the 25 patients stopped chemotherapy due to neurotoxicity. Conclusions: Our data seem to indicate that the co-administration of a neuroprotective agent during BTZ treatment can prevent the appearance/worsening of symptoms related to CIPN, avoiding the interruption of BTZ and maintaining valuable functional autonomy to allow normal daily activities. We believe that prevention remains the mainstay to preserve QoL in this particular patient population, and that future studies with a larger patient population are needed. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1534-7354 1552-695X 15347354 |
| Relation: | https://doaj.org/toc/1534-7354; https://doaj.org/toc/1552-695X |
| DOI: | 10.1177/1534735419888584 |
| Access URL: | https://doaj.org/article/f082617453644d40ae65f0da9894189c |
| Accession Number: | edsdoj.f082617453644d40ae65f0da9894189c |
| Database: | Directory of Open Access Journals |
| ISSN: | 15347354 1552695X |
|---|---|
| DOI: | 10.1177/1534735419888584 |
| Published in: | Integrative Cancer Therapies |
| Language: | English |